Article Sidebar

PDF
Date Published: 28/12/2025
Abstract Views: 0
Views PDF: 0
DOI: 10.56535/jmpm.v50i9.1326
Issue
Vol. 50 No. 9 (2025): JOURNAL OF MILITARY PHARMACO-MEDICINE No.9 - 2025
Section
Articles
How to Cite
Nguyen, D. V., Tran, V. D., Vu, H. H., Nguyen, T. H., & Nguyen, D. T. (2025). FACTORS RELATED TO ARRHYTHMIA IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY WITH AN ANTHRACYCLINE REGIMEN. Journal of Military Pharmaco-medicine, 50(9), 44-52. https://doi.org/10.56535/jmpm.v50i9.1326

FACTORS RELATED TO ARRHYTHMIA IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY WITH AN ANTHRACYCLINE REGIMEN

Dinh Viet Nguyen1, , Van Dong Tran2, Hoc Huan Vu3, Thi Hien Nguyen1, Duc Thuan Nguyen4
1 Bệnh viện Đa khoa tỉnh Phú Thọ
2 Bệnh viện Bạch Mai
3 Bệnh viện Đa khoa Quốc tế Hải Phòng
4 Học viện Quân y

Main Article Content

Abstract

Objectives: To investigate several factors associated with arrhythmia in breast cancer patients receiving anthracycline-based chemotherapy regimens. Methods: A respective, cross-sectional descriptive study was conducted on 52 breast cancer patients treated at Phu Tho Provincial General Hospital from August 2021 to September 2022. Clinical characteristics, treatment regimens, cancer stages, and manifestations of arrhythmias were collected and statistically analyzed. Results:Patients < 50 years of age had a significantly higher rate of arrhythmia compared to those aged ≥ 50 (p < 0.05). Sinus tachycardia was the most common type of arrhythmia, more prevalent in patients < 50 years, those receiving high-dose ACT regimens, and those at advanced cancer stages (III, IV) compared to other groups (p < 0.05). Conclusion: Arrhythmia in breast cancer patients treated with anthracycline is associated with age, chemotherapy regimen, and cancer stage. Cardiac monitoring should be emphasized in high-risk groups to minimize complications and improve overall treatment effectiveness.

Keywords

Breast cancer, Anthracycline, Arrhythmia, Sinus tachycardia, Chemotherapy

Article Details

References

1. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine. 1979; 91(5):710-717.
2. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman G. Early and late arrhythmogenic effects of doxorubicin. Southern Medical Journal. 2007; 100(3):262-265.
3. Zhou W, Chen S, Xu F, Zeng X. Survival benefit of pure dose-dense chemotherapy in breast cancer: A meta-analysis of randomized controlled trials. World Journal of Surgical Oncology. 2018; 16(1):144.
4. Blondeaux E, Lambertini M, Michelotti A, Conte B, Benasso M, Dellepiane C, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. Br J Cancer. 2020; 122(11):1611-1617.
5. Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008; 26(8):1216-1222.
6. Mauro E, Lucà F, Tetta C, Parise O, Parrini I, Parise G, et al. Breast cancer and atrial fibrillation. Journal of Clinical Medicine. 2022; 11(5).
7. Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy. 2021; 139:111708.
8. Anker MS, Frey MK, Goliasch G, Bartko PE, Prausmüller S, Gisslinger H, et al. Increased resting heart rate and prognosis in treatment-naïve unselected cancer patients: Results from a prospective observational study. European Journal of Heart Failure. 2020; 22(7):1230-1238.